Clinical Trials Logo

Ischemic Heart Disease clinical trials

View clinical trials related to Ischemic Heart Disease.

Filter by:

NCT ID: NCT03700645 Not yet recruiting - Diabetes Mellitus Clinical Trials

Allopurinol in Diabetes Mellitus and Multivessel Coronary Artery Disease

Start date: October 1, 2018
Phase: Phase 4
Study type: Interventional

Atherosclerosis is a progressive disease of the arterial wall, arising from the combination of endothelial dysfunction and inflammation. This link is exacerbated in diabetic patients. Uric acid is known to generate oxidative stress and it's elevated levels has been shown to be associated with cardiac hypertrophy, inflammation, myocardial fibrosis and diastolic dysfunction. Allopurinol inhibits xanthine oxidase, an enzyme that regulates uric acid production. In observational studies it has been shown to reduce ischemia, inflammation and improve coronary flow. The aim of this study is to see whether treatment with Allopurinol in patients diagnosed with multivessel disease and undergoing treatment with either percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG) , will reduce markers of inflammation and improve quality of life and major adverse cardiovascular effects (MACE).

NCT ID: NCT03688815 Completed - Clinical trials for Ischemic Heart Disease

Dipyridamole Induced Ischemia and Biomarkers

Start date: January 1, 2009
Study type: Observational

Analysis of certain biomarkers and transient myocardial perfusion deficit revealed by myocardial perfusion scintigraphy.

NCT ID: NCT03660657 Not yet recruiting - Clinical trials for Ischemic Heart Disease

Ozone Therapy in Refractory Ischemic Heart Disease.

Start date: October 2018
Phase: Phase 2/Phase 3
Study type: Interventional

The main objective of this clinical trial is to evaluate the effectiveness and cost-effectiveness of adding ozone therapy to standard management of patients with advanced ischemic heart disease refractory to medical and surgical treatment.

NCT ID: NCT03651791 Completed - Clinical trials for Ischemic Heart Disease

In Vivo Tracking of USPIO Labeled MSC in the Heart

Start date: May 2013
Phase: Phase 1
Study type: Interventional

To evaluate the ability to trace iron oxide-labeled mesenchymal stromal cells with magnetic resonance imaging (MRI) after NOGA-guided injection therapy into the myocardium in patients with ischemic heart disease.

NCT ID: NCT03629158 Enrolling by invitation - Clinical trials for Coronary Artery Disease

Brief Behavioral Health Intervention Program for Patients With Stable Coronary Artery Disease

Start date: September 11, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the effectiveness of a lifestyle intervention for patients living with stable coronary artery disease (CAD). One group will receive the the intervention, and the other will receive treatment as usual (TAU). The investigators hypothesize that, compared to the TAU group, participants receiving the intervention will 1) experience greater confidence in managing their cardiac disease, as indicated by perceived self-efficacy and illness perceptions; 2) experience greater psychological adjustment as indicated by depressive, anxious, and demoralization symptoms; 3) experience greater engagement in health behaviors including healthy eating and physical activity.

NCT ID: NCT03619395 Not yet recruiting - Clinical trials for Acute Coronary Syndrome

Risc Optimisation- Acute cor5onary Syndrome

Start date: September 1, 2018
Study type: Observational [Patient Registry]

This study evaluates the percentage of patients that reach the objective levels of LDL cholesterol, glycosylated hemoglobin and blood pressure recommended by clinical guidelines after an acute coronary syndrome, following strategies of pharmacological optimization based on algorithms. The investigators hypothesize that the use of algorithms designed and protocolized within a cardiac rehabilitation program after an ACS to optimize pharmacological treatment is effective and safe to improve the control of risk factors in patients with high cardiovascular risk.

NCT ID: NCT03613064 Not yet recruiting - Clinical trials for Coronary Artery Disease

Addressing Social Vulnerabilities in Cardiovascular Disease

Start date: June 2019
Phase: N/A
Study type: Interventional

The investigators will conduct a feasibility study of an enhanced transitional care intervention, that will: 1) automate identification and risk-stratification of patients with CHF and IHD with social vulnerabilities; 2) incorporate a new standardized social vulnerabilities screening tool into clinical care; 3) enable electronic referrals to community resources; and 4) add novel community-based interventions to the existing medically-oriented transitional care intervention that is the standard of care at the study hospital (Parkland Hospital in Dallas, Texas) and other hospitals nationwide.

NCT ID: NCT03600961 Recruiting - Clinical trials for Ischemic Heart Disease

BIOFLOW-SV Portugal Registry

Start date: May 18, 2018
Study type: Observational

Assessment of the clinical safety and performance of the Orsiro drug-eluting stent in a real world setting in patients with small vessels with reference vessel diameter ≤2.75 mm

NCT ID: NCT03586492 Recruiting - Clinical trials for Ischemic Heart Disease

Coronary Flow Reserve (CFR) in Cardiovascular Risk Stratification

Start date: November 5, 2018
Phase: N/A
Study type: Interventional

CFR has been studied for few years using 82 Rubidium PET (positron emission tomography) /CT. CFR has shown to be correlated with cardiovascular events occurring in the 10 following years. CFR also helps to identify multivessel coronary disease. Few studies have shown the possibility to calculate CFR during myocardial perfusion SPECT on new ultrafast CZT cameras.

NCT ID: NCT03583320 Recruiting - Clinical trials for Coronary Artery Disease

Trial of Cardiac CT in Acute Chest Patients With Intermediate Level Initial High-sensitivity Cardiac Troponin

Start date: January 12, 2018
Phase: N/A
Study type: Interventional

Patients who present to the emergency department (ED) with acute chest pain (ACP) possibly due to Coronary artery disease (CAD), with a normal heart tracing (ECG), need to have further troponin blood tests to confirm or exclude a heart attack. After initial troponin testing, a significant 50-85% of patients are said to be in an "observational zone" as one cannot confirm or exclude a diagnosis of a heart attack. Even after repeat blood testing, 22-33% remain in this "observational zone". These patients can be challenging to manage as they are not safe to be discharged home, but they also cannot be treated as a heart attack. This contributes to ED overcrowding and uncertainty in treatment plans.